Thursday, December 21, 2023
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has revealed a significant development for its newly established Rentschler Biopharma Manufacturing Center (RBMC) facility in Milford, Massachusetts. The RBMC, set to become operational in the latter half of 2024, has secured a major client for the production of a leading cancer therapeutic.
The client, a longstanding partner of Rentschler Biopharma based in Germany, has chosen to manufacture its product lead at the RBMC for clinical supply. This decision follows the successful production of cGMP-quality products for early-phase clinical trials at Rentschler Biopharma's manufacturing site in Laupheim, Germany. The next phase of the project will involve the transfer of production to the RBMC in the U.S. to meet additional supply requirements.
Federico Pollano, Senior Vice President of Business Development at Rentschler Biopharma, expressed satisfaction with the client's decision and emphasized the company's commitment to seamless operations across global sites, focusing on the consistent delivery of high-quality products. Pollano looks forward to cultivating partnerships with both new and existing clients at the advanced U.S. facility.
Benedikt von Braunmühl, CEO of Rentschler Biopharma, underscored the company's dedication to simplifying biopharmaceutical manufacturing for clients. He highlighted the RBMC's adaptability to evolving needs, emphasizing the strategic importance of U.S. operations in expanding international capabilities. The announcement reaffirms Rentschler Biopharma's role as a comprehensive provider of development and production solutions in the biopharmaceutical industry.
The Milford site has undergone significant evolution, transforming from a single-product commercial facility to a multifaceted production site with up to 500 L bioreactor setups. The RBMC, featuring 22,000 square feet of manufacturing cleanroom space and equipped with four new 2,000 L single-use bioreactors, represents the largest expansion in Rentschler Biopharma's 150-year history. This facility is poised to double the company's global cGMP capacity, with a primary focus on the commercial production of intricate molecules for international clients.
Source: globenewswire.com
